FindTrial
Sign In

Vactosertib

DRUG9 trials

Sponsors

Koen van Besien, Chloe Atreya, MD, PhD, Weill Medical College of Cornell University, Samsung Medical Center, David Wald

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdenocarcinoma EsophagusChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaColorectal CancerDermoidEsophageal Cancer

Phase 1

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
CompletedNCT03143985
Koen van BesienMultiple Myeloma
Start: 2017-07-21End: 2022-09-01Updated: 2024-05-24
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
NCT04258072
Samsung Medical CenterPancreas Cancer
Start: 2021-04-19End: 2023-03-31Target: 24Updated: 2022-06-15
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
SuspendedNCT05400122
David WaldAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +15
Start: 2022-09-09End: 2026-06-01Target: 12Updated: 2025-11-12
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
RecruitingNCT05588648
MedPacto, Inc.Osteosarcoma
Start: 2023-05-01End: 2025-12-31Target: 48Updated: 2025-04-10

Phase 2

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
TerminatedNCT03844750
Chloe Atreya, MD, PhDMetastatic Malignant Neoplasm in the Liver, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8 +2
Start: 2019-07-22End: 2025-09-30Updated: 2025-12-31
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
TerminatedNCT04103645
Weill Medical College of Cornell UniversityMyeloproliferative Neoplasm
Start: 2019-11-22End: 2024-07-10Updated: 2025-07-02
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
NCT04656002
Samsung Medical CenterGastric Cancer
Start: 2022-10-31End: 2024-12-31Target: 43Updated: 2022-06-15
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
RecruitingNCT06044311
Sakti ChakrabartiAdenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction +1
Start: 2024-09-30End: 2027-06-01Target: 25Updated: 2025-02-24
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
WithdrawnNCT06219733
MedPacto, Inc.Dermoid
Start: 2021-06-01End: 2022-05-23Updated: 2024-12-09

Related Papers

A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for locally advanced esophageal adenocarcinoma.
Journal of Clinical Oncology2025-01-27
The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial
Blood2024-11-05
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.
2024-08-2716 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.
Journal of Clinical Oncology2023-01-243 citations
Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/<i>nab</i>-paclitaxel.
Journal of Clinical Oncology2022-01-192 citations
Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.
Journal of Clinical Oncology2021-05-208 citations
Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway
Blood2019-11-136 citations
Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors
Blood2018-11-299 citations
Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide
Blood2018-11-297 citations